Retraction
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE
Paper Information
Record ID:
24119
Author(s):
Journal:
Publication Date:
December 15, 2017
Retraction Date:
August 21, 2020
(5.3 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institutions:
- The Royal Marsden NHS Foundation Trust, London
- Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom
- Centro de Referência da Saúde da Mulher
- Hospital Israelita Albert Einstein, São Paulo, Brazil
- Seoul National University College of Medicine, Seoul
- National Cancer Center, Gyeonggi-do, Korea
- Regional Oncology Dispensary, Arkhangelsk
- N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
- Galina Kurteva, University Cancer Center Hospital, Sofia, Bulgaria
- University of Southern California, Los Angeles, CA
- Aichi Cancer Center Hospital, Aichi, Japan
- Novartis Pharma AG, Basel, Switzerland
- Northwestern University, Chicago, IL
Countries:
Article Type:
Publisher:
American Society of Clinical Oncology
Open Access:
No
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1200/JCO.20.02029Additional Notes:
see also: https://ascopubs.org/doi/abs/10.1200/JCO.20.01894;
Citations (157)
157
Total Citations109
Post-Retraction(69.4%)
47
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
28
Within 1 year
60
After 2+ years
1678
Days since retraction (latest)
Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
Huimin Lv, Min Yan, Zefei Jiang
Therapeutic Advances in Medical Oncology
Open Access
Published: Jan 2021
13 citations
13 citations
133 days after retraction
The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China
Xinzhao Wang, Lin Wang, Qian Yu et al. (7 authors)
Technology in Cancer Research & Treatment
Open Access
Published: Jan 2021
10 citations
10 citations
133 days after retraction
Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study
Deyue Liu, Jiayi Wu, Cai-Jin Lin et al. (7 authors)
Frontiers in Oncology
Open Access
Published: Dec 2020
51 citations
51 citations
103 days after retraction
Tyrosine Kinase Receptors in Oncology
Jorge Esteban-Villarrubia, J.J. Soto Castillo, Javier Pozas et al. (9 authors)
International Journal of Molecular Sciences
Open Access
Published: Nov 2020
79 citations
79 citations
83 days after retraction
Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication
Manuela Costantini, Carla Azzurra Amoreo, Liborio Torregrossa et al. (19 authors)
Cancers
Open Access
Published: Nov 2020
6 citations
6 citations
83 days after retraction
Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
Eirini Thanopoulou, Leila Khader, Morena Caira et al. (8 authors)
Cancers
Open Access
Published: Nov 2020
28 citations
28 citations
81 days after retraction
Protein Binding of Lapatinib and Its N- and O-Dealkylated Metabolites Interrogated by Fluorescence, Ultrafast Spectroscopy and Molecular Dynamics Simulations
Inmaculada Andreu, Emilio Lence, Concepción González‐Bello et al. (7 authors)
Frontiers in Pharmacology
Open Access
Published: Oct 2020
13 citations
13 citations
70 days after retraction
Should triple-positive breast cancer be recognized as a distinct subtype?
Maria Vittoria Dieci, Valentina Guarneri
Expert Review of Anticancer Therapy
Open Access
Published: Oct 2020
21 citations
21 citations
46 days after retraction
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars
Megan E. Tesch, Karen A. Gelmon
Drugs
Published: Oct 2020
37 citations
37 citations
46 days after retraction
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
Stephen Johnston, Roberto Hegg, Seock‐Ah Im et al. (15 authors)
Journal of Clinical Oncology
Open Access
Published: Aug 2020
103 citations
103 citations
Same day as retraction
Systemic therapy for metastatic HER2-positive breast cancer
Philip Bredin, Janice M. Walshe, Neelima Denduluri
Seminars in Oncology
Published: Aug 2020
66 citations
66 citations
3 days before retraction
A Novel Prognostic Nomogram for 2-Year Survival in HER2-Positive Breast Cancer Patients
Mengdi Chen, Jiayi Wu, Deyue Liu et al. (9 authors)
Research Square (Research Square)
Open Access
Published: Aug 2020
10 days before retraction
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Aena Patel, Nisha Unni, Yan Peng
Cancers
Open Access
Published: Jul 2020
120 citations
120 citations
24 days before retraction
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
Changjun Wang, Yan Lin, Yidong Zhou et al. (13 authors)
BMC Cancer
Open Access
Published: Jul 2020
11 citations
11 citations
39 days before retraction
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Maria Vittoria Dieci, Federica Miglietta, Gaia Griguolo et al. (4 authors)
Cancer Treatment Reviews
Open Access
Published: Jun 2020
60 citations
60 citations
57 days before retraction
Dual HER-2 blockade therapy increases the risk of developing cardiac toxicities in HER-2 positive breast cancer: an up-to-date comprehensive meta-analysis
Wei‐Xiang Qi, Lu Cao, Cheng Xu et al. (5 authors)
Authorea (Authorea)
Open Access
Published: Jun 2020
58 days before retraction
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
Adam S. Komorowski, Helen Mackay, Rossanna C. Pezo
Cancer Medicine
Open Access
Published: May 2020
9 citations
9 citations
87 days before retraction
Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials
Alyson Haslam, Diana Herrera-Perez, Jennifer Gill et al. (4 authors)
JAMA Network Open
Open Access
Published: Mar 2020
81 citations
81 citations
170 days before retraction
Real‐world data of lapatinib and treatment after lapatinib in patients with previously treated HER2‐positive metastatic breast cancer: A multicenter, retrospective study
Yizhao Xie, Rui Ge, Die Sang et al. (8 authors)
Cancer Medicine
Open Access
Published: Feb 2020
6 citations
6 citations
175 days before retraction
Dual HER-2 blockade therapy increases the risk of developing cardiac toxicities in HER-2 positive breast cancer: an up-to-date comprehensive meta-analysis
Wei‐Xiang Qi, Lu Cao, Cheng Xu et al. (5 authors)
Research Square (Research Square)
Open Access
Published: Feb 2020
178 days before retraction
Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study
Fei Xu, Kaping Lee, Wen Xia et al. (15 authors)
The Oncologist
Open Access
Published: Feb 2020
4 citations
4 citations
189 days before retraction
Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy
Zhaoqian Liu, Chen‐Xue Mao, Ji‐Ye Yin
Springer eBooks
Published: Jan 2020
1 citation
1 citation
233 days before retraction
Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database
Zeina Nahleh, Elizabeth Blessing Elimimian, Leah Elson et al. (6 authors)
Breast Cancer Basic and Clinical Research
Open Access
Published: Jan 2020
3 citations
3 citations
233 days before retraction
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Jordyn Kreutzfeldt, Brett J. Rozeboom, Nandini Dey et al. (4 authors)
PubMed
Published: Jan 2020
140 citations
140 citations
233 days before retraction
Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
Xue Yang, Dapeng Wu, Shengli Yuan
Technology in Cancer Research & Treatment
Open Access
Published: Jan 2020
20 citations
20 citations
233 days before retraction
Towards personalized treatment for early stage HER2-positive breast cancer
Kristina Goutsouliak, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath et al. (7 authors)
Nature Reviews Clinical Oncology
Open Access
Published: Dec 2019
251 citations
251 citations
252 days before retraction
Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
Abby Statler, Brian P. Hobbs, Wei Wei et al. (6 authors)
Scientific Reports
Open Access
Published: Dec 2019
38 citations
38 citations
263 days before retraction
What therapies are on the horizon for HER2 positive breast cancer?
Giulia Viale, Stefania Morganti, Emanuela Ferraro et al. (6 authors)
Expert Review of Anticancer Therapy
Published: Aug 2019
4 citations
4 citations
361 days before retraction
Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. Octava revisión. Colima 2019
Jesús Cárdenas-Sánchez, Aura Argentina Erazo-Valle-Solís, Claudia Arce-Salinas et al. (14 authors)
Gaceta Mexicana de Oncología
Open Access
Published: Aug 2019
12 citations
12 citations
381 days before retraction
HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
Akio Kaito, Takeshi Kuwata, Masanori Tokunaga et al. (7 authors)
World Journal of Clinical Cases
Open Access
Published: Aug 2019
49 citations
49 citations
381 days before retraction
Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment
Ada Koschorke, Simona Faraci, Debora Giani et al. (16 authors)
Cellular Oncology
Published: Aug 2019
17 citations
17 citations
385 days before retraction
Excellent Response to Oral Etoposide in HER2-Positive Metastatic Breast Cancer (MBC)
Manikandan Dhanushkodi, Priya Iyer, Balasubramanian Ananthi et al. (5 authors)
Indian Journal of Gynecologic Oncology
Published: Jul 2019
2 citations
2 citations
393 days before retraction
HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology
Étienne Brain, Philippe Caillet, Nienke A. de Glas et al. (7 authors)
Journal of Geriatric Oncology
Open Access
Published: Jun 2019
45 citations
45 citations
426 days before retraction
Investigational drugs in early stage clinical trials for the treatment of HER2+ breast cancer
Andrea Gombos, Maria Alice Franzoi, Ahmad Awada
Expert Opinion on Investigational Drugs
Published: Jun 2019
8 citations
8 citations
426 days before retraction
New strategies for the precision treatment of HER2-driven tumours
Helena Gouveia, Assia Konsulova, Fátima Cardoso
Expert Review of Precision Medicine and Drug Development
Published: Jun 2019
438 days before retraction
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Qiao Li, Xiuwen Guan, Shanshan Chen et al. (19 authors)
Clinical Cancer Research
Open Access
Published: May 2019
73 citations
73 citations
451 days before retraction
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives
Claudio Vernieri, Monica Milano, Marta Brambilla et al. (13 authors)
Critical Reviews in Oncology/Hematology
Published: May 2019
197 citations
197 citations
476 days before retraction
Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer
Marie-France Savard, Omar Farooq Khan, Kelly K. Hunt et al. (4 authors)
American Society of Clinical Oncology Educational Book
Published: May 2019
27 citations
27 citations
478 days before retraction
Enthuse for PERUSE: when clinical judgment overcomes regulatory boundaries
Valentina Guarneri
Annals of Oncology
Open Access
Published: Mar 2019
1 citation
1 citation
525 days before retraction
Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases
Shireen Parsai, Jacob A. Miller, Aditya Juloori et al. (13 authors)
Journal of neurosurgery
Published: Feb 2019
51 citations
51 citations
541 days before retraction
Comparison of 4th ESO–ESMO international consensus guidelines for advance breast cancer and Chinese anti-cancer association committee of Breast Cancer Society guideline
Xichun Hu, Ting Li, Biyun Wang et al. (6 authors)
The Breast
Open Access
Published: Feb 2019
15 citations
15 citations
546 days before retraction
The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer
Chi Zhang, Ying Guo, Jiyu Li et al. (5 authors)
Medicine
Open Access
Published: Jan 2019
1 citation
1 citation
568 days before retraction
Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis
Joseph M. Kim, Jacob A. Miller, Rupesh Kotecha et al. (15 authors)
Neuro-Oncology
Open Access
Published: Jan 2019
48 citations
48 citations
591 days before retraction
Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
Emilia Montagna, Marco Colleoni
Therapeutic Advances in Medical Oncology
Open Access
Published: Jan 2019
22 citations
22 citations
598 days before retraction
Treatment of HER2-Overexpressing Metastatic Breast Cancer
Adnan Aydıner
Breast Disease
Published: Jan 2019
598 days before retraction
Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.
Juncheng Xuhong, Xiaowei Qi, Yi Zhang et al. (4 authors)
PubMed
Published: Jan 2019
124 citations
124 citations
598 days before retraction
Systemic Treatment of HER2-Overexpressing Metastatic Breast Cancer
Adnan Aydıner
Breast Cancer
Published: Oct 2018
1 citation
1 citation
662 days before retraction
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer
Andrew D. Seidman, Louise Bordeleau, Louis Fehrenbacher et al. (17 authors)
Journal of Clinical Oncology
Open Access
Published: Sep 2018
24 citations
24 citations
708 days before retraction
Clinical benefit of fulvestrant monotherapy in the multimodal treatment of hormone receptor and HER2 positive advanced breast cancer: a case series
Orsolya Rusz, Renáta Kószó, Ágnes Dobi et al. (9 authors)
OncoTargets and Therapy
Open Access
Published: Sep 2018
17 citations
17 citations
720 days before retraction
Metastatic Hormone and Her-2 Positive Breast Cancer: A Community Approach
Ida Micaily
Open Access Journal of Oncology and Medicine
Open Access
Published: Jun 2018
800 days before retraction
Quick Stats
Total Citations:
157
Years Since Retraction:
5.3 years
Open Access:
No
Last Checked:
Jul 24, 2025